# Targeting Activated Pathways in Doxorubicin-Resistant TNBC Alters Signaling, Survival and EMT: A Double-Edged Sword

**Authors:** Irem Dogan Turacli, Sahika Cingir Koker, Kubra Paspal Eroglu, Banu Yalcin

PMC · DOI: 10.3390/ijms27062792 · International Journal of Molecular Sciences · 2026-03-19

## TL;DR

This study explores how inhibiting specific pathways in doxorubicin-resistant triple-negative breast cancer affects cell survival and EMT, revealing both benefits and risks.

## Contribution

The study reveals that combining MEK and PI3K inhibitors is more effective in resistant TNBC cells and highlights EMT as a mediator of resistance.

## Key findings

- Resistant TNBC cells show more aggressive behavior with EMT-related gene expression.
- Combining MEK and PI3K inhibitors is more effective in suppressing signals in resistant cells.
- Doxorubicin resistance may contribute to metastatic characteristics through EMT.

## Abstract

Triple-negative breast cancer (TNBC) poses significant therapeutic challenges due to the limited availability of targeted treatment options and the development of resistance to chemotherapy, including doxorubicin (DOX). The objective of this study was to investigate the impact of inhibiting activated pathways in DOX-resistant TNBC and examine the effects on MAPK and PI3K/Akt signaling pathways, cell cycle regulation, and the regulators of the epithelial–mesenchymal transition (EMT) process. Continuous exposure of cells to increasing concentrations of DOX resulted in the selection of resistant cells that exhibited EMT characteristics. We assessed the expression levels of markers related to cell death, survival, mitophagy pathways and EMT using Western blotting and qPCR in both sensitive and resistant cells with activated-pathway inhibitor treatments. Additionally, we demonstrated differences in migration capacity between resistant and sensitive cells with or without inhibitor treatments. It was found that MEK inhibition was less effective than PI3K inhibition in both sensitive and resistant cells. Expression analyses clearly demonstrated that resistant cells exhibited more aggressive behavior, as indicated by EMT- and survival-related gene expressions. The combination of MEK and PI3K inhibitors was more effective in shutting down these signals in both cell types. The ability to induce EMT in DOX-resistant cells revealed that one form of resistance might combine with another, acting as a mediator for cellular switch. Although drug resistance and various inhibitors reduce the proliferative capacity of cells and related parameters, resistance contributes to the acquisition of metastatic characteristics.

## Linked entities

- **Proteins:** MAP2K7 (mitogen-activated protein kinase kinase 7), PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), AKT1 (AKT serine/threonine kinase 1), MAPK (mitogen activated kinase-like protein)
- **Chemicals:** doxorubicin (PubChem CID 31703)
- **Diseases:** triple-negative breast cancer (MONDO:0005494), breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, MAP2K7 (mitogen-activated protein kinase kinase 7) [NCBI Gene 5609] {aka JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7}
- **Diseases:** TNBC (MESH:D064726)
- **Chemicals:** DOX (MESH:D004317)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13026208/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13026208/full.md

## References

46 references — full list in the complete paper: https://tomesphere.com/paper/PMC13026208/full.md

---
Source: https://tomesphere.com/paper/PMC13026208